A Study to Assess the Effect of CellCept (Mycophenolate Mofetil) and Reduced Corticosteroids in Patients With Active Pemphigus Vulgaris (PV)

Exclusion Criteria

• •Female patients who are pregnant, breastfeeding, or lactating
• •Regularly scheduled plasma exchange (PE) or intravenous immunoglobulin (IVIG) treatment, or PE or IVIG treatment within 8 weeks prior to randomization
• •CellCept or other immunosuppressive therapy, except corticosteroids, exceeding 2 weeks total duration and within 8 weeks prior to randomization
• •Use of PV therapies other than those noted above, within 4 weeks prior to randomization
• •Use of topical corticosteroids within 2 weeks prior to randomization